

## Peer Review File

Article Information: <https://dx.doi.org/10.21037/cco-23-69>

### Reviewer A

*This is an excellent commentary on a journal article “Huang H, Tao R, Hao S, et al. Sugemalimab monotherapy for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (GEMStone-201): Results from a single-arm, multicenter, phase II study. J Clin Oncol 2023, 41(16):3032-3041.” This commentary provided a historical review of therapeutic options for R/R ENKTL with emphasis on PD-1/PD-L1 inhibitors, highlighted the significance of the findings from this phase II Sugemalimab trial, assessed the limitations of the study, and provided directions for future research and clinical trials.*

Reply: We appreciate your question.

### Reviewer B

Minor comments:

1) *Line 181, Table 1: Please include citation on each study for easy reference.*

Reply: We appreciate your question. We have already added the citation for each study in Table 1 on line 185 for easy reference.

2) *Line 38: The authors might want to include brief description for Sintilimab study to make the section more complete.*

Reply: Thank you for your valuable suggestion. On line 34, we have already included a brief description of the Sintilimab study in the relevant section to enhance the completeness of our manuscript.

3) *Line 71: Please include the citation.*

*“Although prior reports have shown no correlation between PD-L1 expression on lymphoma cells and the response to PD1/PD-L1 inhibitors, [citation] two prospective studies have identified a correlation between elevated PDL1 expression levels and improved immunotherapy response [6, 8]. Therefore, further investigation into the predictive value of PD-L1 expression levels for clinical response is warranted, with a larger patient cohort and more comprehensive exploration of biomarker expression.”*

*Citation: Lim et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia. 2020 Dec;34(12):3413-3*

Reply: We appreciate your suggestion. We have already included the citation on line 78.